Lipid nanoparticles in the development of mRNA vaccines for COVID-19
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Coronavirus disease (COVID-19) was first reported in December 2019, Hubei Province, China. As on 9th December 2021, severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) has affected 266018810 people worldwide with 5265092 deaths. The outbreak of COVID-19 pandemic has caused severe public health crisis across the world. Nucleic acids have been emerging as potential drugs to treat a variety of diseases. Lipid nanoparticles (LNPs) have great potential to deliver nucleic acids including mRNAs. The two mRNA-based vaccines namely the BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) have been given emergency use authorization (EUA) by the US-FDA to prevent SARS-CoV-2 caused COVID-19 and the vaccines were developed using LNPs. This article focuses on the potential application of LNPs in the development and delivery of mRNA vaccines for COVID-19.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Engineering precision nanoparticles for drug delivery
Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0090-8 · Cited by 7,933
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667 · cited 8×
“Liposomes can be used to deliver a wide range of substances which include hydrophilic or hydrophobic drugs, diagnostic substances, proteins, DNA and RNA.”
BackgroundInfluentialDirect Gene Transfer into Mouse Muscle in Vivo
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173 · cited 1×
“In the year 1990, successful production of protein was observed in in vitro transcribed (IVT) mRNA injected mice [13].”
BackgroundLipid nanoparticles for mRNA delivery
Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00358-0 · Cited by 4,076
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615 · cited 2×
“The highest neutralization titres were observed on samples collected on 28th day (7th day after the second dose) or 35th day (14th day after the second dose) [64].”
BackgroundTenchov, R., Bird, R., Curtze, A. E., & Zhou, Q. (2021) · ACS Nano · doi:10.1021/acsnano.1c04996 · Cited by 2,221
Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930 · cited 1×
“The uridine in the IVT mRNA can be replaced with pseudouridine and this replacement can increase the RNA stability and decrease anti-RNA immune response [21].”
BackgroundThe Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
Akinc, A., Maier, M. A., Manoharan, M., Fitzgerald, K., Jayaraman, M., Barros, S., Ansell, S., Du, X., Hope, M. J., Madden, T. D., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0591-y · Cited by 1,636
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
A guide to vaccinology: from basic principles to new developments
Pollard, A. J., & Bijker, E. M. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-00479-7 · Cited by 1,593
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery
Kowalski, P. S., Rudra, A., Miao, L., & Anderson, D. G. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.012 · Cited by 1,127 · cited 1×
“After administration, mRNA-LNPs are delivered into the host cells’ cytosol and the mRNA is used as template for the synthesis of protein antigen [22].”
MethodBNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses
Jiang, S., Hillyer, C., & Du, L. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.03.007 · Cited by 847
The accelerated blood clearance (ABC) phenomenon: Clinical challenge and approaches to manage
Abu Lila, A. S., Kiwada, H., & Ishida, T. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.07.026 · Cited by 721 · cited 2×
“BNT162b2, at a dose level of 30 μg, was advanced to phase II/III clinical trials (NCT04368728) [60] and the ongoing trials showed promising results [66].”
BackgroundThe role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery
Cheng, X., & Lee, R. J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.01.022 · Cited by 703
Ndeupen, S., Qin, Z., Jacobsen, S., Bouteau, A., Estanbouli, H., & Igyártó, B. Z. (2021) · iScience · doi:10.1016/j.isci.2021.103479 · Cited by 678
mRNA vaccine delivery using lipid nanoparticles
Reichmuth, A. M., Oberli, M. A., Jaklenec, A., Langer, R., & Blankschtein, D. (2016) · Therapeutic Delivery · doi:10.4155/tde-2016-0006 · Cited by 624
Patel, S., Ashwanikumar, N., Robinson, E., Xia, Y., Mihai, C., Griffith, J. P., Hou, S., Esposito, A. A., Ketova, T., Welsher, K., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14527-2 · Cited by 601 · cited 1×
“Structural modification of cholesterol derivatives increased the cellular uptake of LNPs and trafficking by 25-fold [55].”
BackgroundAdvances in COVID-19 mRNA vaccine development
Fang, E., Liu, X., Li, M., Zhang, Z., Song, L., Zhu, B., Wu, X., Liu, J., Zhao, D., & Li, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00950-y · Cited by 601 · cited 1×
“The Pfizer-BioNTech (BNT162b2) and Moderna (mRNA-1273) vaccines use pseudouridine modifications to ensure the stability of mRNA [20].”
BackgroundKim, J., Eygeris, Y., Gupta, M., & Sahay, G. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.014 · Cited by 514 · cited 6×
“It is important that the structure and concentration of PEG-lipid to be optimized to maintain the stealth effect of LNPs [3].”
BackgroundMethodInfluentialOrlandini von Niessen, A. G., Poleganov, M. A., Rechner, C., Plaschke, A., Kranz, L. M., Fesser, S., Diken, M., Löwer, M., Vallazza, B., Beissert, T., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2018.12.011 · Cited by 365
Wilson, B., Samanta, M. K., Santhi, K., Kumar, K. P. S., Paramakrishnan, N., & Suresh, B. (2008) · Brain Research · doi:10.1016/j.brainres.2008.01.039 · Cited by 363
Self-citationMicrofluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems
Leung, A. K. K., Tam, Y. Y. C., Chen, S., Hafez, I. M., & Cullis, P. R. (2015) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.5b02891 · Cited by 359
Novel approaches for vaccine development
Gebre, M. S., Brito, L. A., Tostanoski, L. H., Edwards, D. K., Carfi, A., & Barouch, D. H. (2021) · Cell · doi:10.1016/j.cell.2021.02.030 · Cited by 347 · cited 2×
“Therefore, after the process of endocytosis, ionizable lipids become protonated and positively charged which may enhance destabilization of membrane and helps endosomal escape of LNPs and deliver the encapsulated material into the cytosol and there the mRNA is translated into antigenic proteins which stimulates the pr…”
BackgroundFotin-Mleczek, M., Duchardt, K. M., Lorenz, C., Pfeiffer, R., Ojkić-Zrna, S., Probst, J., & Kallen, K.-J. (2011) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181f7dbe8 · Cited by 335 · cited 1×
“mRNAs have self-adjuvanting characteristics as they have the ability to bind with toll-like receptor 7 (TLR7) and improve cellular immunity [17].”
BackgroundAn Orthogonal Array Optimization of Lipid-like Nanoparticles for mRNA Delivery in Vivo
Li, B., Luo, X., Deng, B., Wang, J., McComb, D. W., Shi, Y., Gaensler, K. M. L., Tan, X., Dunn, A. L., Kerlin, B. A., et al. (2015) · Nano Letters · doi:10.1021/acs.nanolett.5b03528 · Cited by 261
Blakney, A. K., McKay, P. F., Yus, B. I., Aldon, Y., & Shattock, R. J. (2019) · Gene Therapy · doi:10.1038/s41434-019-0095-2 · Cited by 206 · cited 1×
“This method showed significant nucleic acid encapsulation efficiency and the encapsulated mRNA molecule is protected from degradation by nuclease enzymes [49].”
MethodNanoplatforms for mRNA Therapeutics
Meng, C., Chen, Z., Li, G., Welte, T., & Shen, H. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202000099 · Cited by 130 · cited 2×
“Further, the interaction between the neutral lipids and the blood cell membranes is less, hence improve the LNPs’ biocompatibility [44].”
BackgroundEffects of Poly(ethylene glycol) (PEG) Concentration on the Permeability of PEG-Grafted Liposomes
Hashizaki, K., Taguchi, H., Itoh, C., Sakai, H., Abe, M., Saito, Y., & Ogawa, N. (2005) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.53.27 · Cited by 46 · cited 2×
“The chemical structure of PEG-lipid, the hydrophilic region and the hydrophobic region, influences the size, penetration across lipid membranes and immune reactions [59,60].”
Background
Cited by
Nanotechnology in healthcare, and its safety and environmental risks
Ma, X., Tian, Y., Yang, R., Wang, H., Allahou, L. W., Chang, J., Williams, G., Knowles, J. C., & Poma, A. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02901-x · Cited by 332
How Can ChatGPT Benefit Pharmacy: A Case Report on Review Writing
Zhu, Y., Han, D., Chen, S., Zeng, F., & Wang, C. (2023) · doi:10.20944/preprints202302.0324.v1 · Cited by 21
Metadata
- Authors
- Wilson, B., & Geetha, K. M.
- Venue
- Journal of Drug Delivery Science and Technology
- Publisher
- Elsevier BV
- Published
- 2022-08
- Volume
- 74
- Pages
- 103553
- ISSN
- 1773-2247 (ISSN-L)
- OpenAlex
- W4283710460
- Cited by
- 245
- References
- 32
- FWCI
- 13.60
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.